Three Candidate Genes and Angiotensin-Converting Enzyme Inhibitor–Related Cough

Three candidate genes and angiotensin-converting enzyme inhibitor-related cough: a pharmacogenetic analysis.

Unexplained, persistent cough limits the use of angiotensin-converting enzyme (ACE) inhibitors in a significant number of patients. It has been speculated that occurrence of this adverse effect is genetically predetermined; in particular, variants of the genes encoding ACE, chymase, and B2-bradykinin receptor have been implicated. To investigate this question, we determined genotypes for common...

Angiotensin Converting Enzyme in Sarcoidosis

Bronchial hyperreactivity and cough due to angiotensin-converting enzyme inhibitors.

Seventeen patients using angiotensin-converting enzyme (ACE) inhibitors for hypertension were evaluated with baseline spirometry followed by determination of bronchial reactivity by challenge with methacholine. There were nine coughers and eight noncoughers in the study. Among the nine coughers, eight demonstrated bronchial hyperreactivity. Conversely, none of the noncoughers disclosed bronchia...

Angiotensin converting enzyme (ACE) inhibitor-induced cough and substance P.

BACKGROUND Angiotensin converting enzyme (ACE) inhibitors cause coughing in 5-10% of patients, but the exact mechanisms of this effect are still unclear. In the airways ACE degrades substance P so the cough mechanism may be related to this peptide. METHODS Nine patients who developed a cough and five patients who did not develop a cough when taking the ACE inhibitor enalapril (2.5 or 5.0 mg/d...

angiotensin converting enzyme in sarcoidosis

0